362 related articles for article (PubMed ID: 19883755)
1. Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice.
Moreno D; Zalba S; Navarro I; Tros de Ilarduya C; Garrido MJ
Eur J Pharm Biopharm; 2010 Feb; 74(2):265-74. PubMed ID: 19883755
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice.
Kim JH; Kim YS; Park K; Lee S; Nam HY; Min KH; Jo HG; Park JH; Choi K; Jeong SY; Park RW; Kim IS; Kim K; Kwon IC
J Control Release; 2008 Apr; 127(1):41-9. PubMed ID: 18234388
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cisplatin cytotoxicity delivered from PLGA-systems.
Moreno D; de Ilarduya CT; Bandrés E; Buñuales M; Azcona M; García-Foncillas J; Garrido MJ
Eur J Pharm Biopharm; 2008 Mar; 68(3):503-12. PubMed ID: 17881198
[TBL] [Abstract][Full Text] [Related]
4. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate.
Li X; Li R; Qian X; Ding Y; Tu Y; Guo R; Hu Y; Jiang X; Guo W; Liu B
Eur J Pharm Biopharm; 2008 Nov; 70(3):726-34. PubMed ID: 18634874
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil.
Yadav AK; Agarwal A; Rai G; Mishra P; Jain S; Mishra AK; Agrawal H; Agrawal GP
Drug Deliv; 2010 Nov; 17(8):561-72. PubMed ID: 20738221
[TBL] [Abstract][Full Text] [Related]
6. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells.
Yallapu MM; Gupta BK; Jaggi M; Chauhan SC
J Colloid Interface Sci; 2010 Nov; 351(1):19-29. PubMed ID: 20627257
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
8. Biopharmaceutic and pharmacodynamic modeling of the in vitro antiproliferative effect of new controlled delivery systems of cisplatin.
Moreno D; Zalba S; Colom H; Trocóniz IF; Tros de Ilarduya C; Garrido MJ
Eur J Pharm Sci; 2009 Jun; 37(3-4):341-50. PubMed ID: 19491025
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: synthesis, antitumor efficiency in vivo and penetration in tumors.
Ding D; Zhu Z; Liu Q; Wang J; Hu Y; Jiang X; Liu B
Eur J Pharm Biopharm; 2011 Sep; 79(1):142-9. PubMed ID: 21272637
[TBL] [Abstract][Full Text] [Related]
10. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
Wang ZH; Wang ZY; Sun CS; Wang CY; Jiang TY; Wang SL
Biomaterials; 2010 Feb; 31(5):908-15. PubMed ID: 19853292
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
Danhier F; Lecouturier N; Vroman B; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
J Control Release; 2009 Jan; 133(1):11-7. PubMed ID: 18950666
[TBL] [Abstract][Full Text] [Related]
12. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting.
Chung YI; Kim JC; Kim YH; Tae G; Lee SY; Kim K; Kwon IC
J Control Release; 2010 May; 143(3):374-82. PubMed ID: 20109508
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution of antisense nanoparticles in mammary carcinoma rat model.
Elazar V; Adwan H; Rohekar K; Zepp M; Lifshitz-Shovali R; Berger MR; Golomb G
Drug Deliv; 2010 Aug; 17(6):408-18. PubMed ID: 20429847
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable polymeric system for cisplatin delivery: development, in vitro characterization and investigation of toxicity profile.
Alam N; Khare V; Dubey R; Saneja A; Kushwaha M; Singh G; Sharma N; Chandan B; Gupta PN
Mater Sci Eng C Mater Biol Appl; 2014 May; 38():85-93. PubMed ID: 24656356
[TBL] [Abstract][Full Text] [Related]
15. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
Yalcin M; Bharali DJ; Lansing L; Dyskin E; Mousa SS; Hercbergs A; Davis FB; Davis PJ; Mousa SA
Anticancer Res; 2009 Oct; 29(10):3825-31. PubMed ID: 19846915
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis.
Kumar G; Sharma S; Shafiq N; Pandhi P; Khuller GK; Malhotra S
Drug Deliv; 2011 Jan; 18(1):65-73. PubMed ID: 20735202
[TBL] [Abstract][Full Text] [Related]
17. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
[TBL] [Abstract][Full Text] [Related]
18. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.
Tseng CL; Su WY; Yen KC; Yang KC; Lin FH
Biomaterials; 2009 Jul; 30(20):3476-85. PubMed ID: 19345990
[TBL] [Abstract][Full Text] [Related]
19. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles.
Niu X; Zou W; Liu C; Zhang N; Fu C
Drug Dev Ind Pharm; 2009 Nov; 35(11):1375-83. PubMed ID: 19832638
[TBL] [Abstract][Full Text] [Related]
20. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.
Mittal G; Sahana DK; Bhardwaj V; Ravi Kumar MN
J Control Release; 2007 May; 119(1):77-85. PubMed ID: 17349712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]